Boramae Urology

Medicine & Life Sciences

1. Prostate 100%
2. Prostatic Hyperplasia 54%
3. Prostatic Neoplasms 48%
4. Volatilization 44%
5. Lower Urinary Tract Symptoms 43%
6. Solid-State Lasers 40%
7. Prostatectomy 40%
8. Prostate-Specific Antigen 28%
9. Erectile Dysfunction 26%
10. Urinary Bladder 25%
11. Overactive Urinary Bladder 24%
12. Urodynamics 23%
13. Biopsy 21%
14. Suburethral Slings 20%
15. Kidney 20%
16. Urinary Bladder Neck Obstruction 19%
17. Urinary Incontinence 18%
18. Renal Cell Carcinoma 18%
19. Korea 17%
20. Recurrence 16%
21. Tamsulosin 16%
22. Crush Injuries 15%
23. Nephrectomy 14%
24. Internet 14%
25. Stress Urinary Incontinence 14%
26. Therapeutics 14%
27. Percutaneous Nephrolithotomy 13%
28. Seoul 13%
29. Quality of Life 13%
30. Safety 12%
31. Lasers 12%
32. Nerve Crush 12%
33. Survival 12%
34. Premature Ejaculation 12%
35. Lim Kinases 12%
36. Neoplasm Grading 11%
37. Fibrosis 11%
38. Prospective Studies 11%
39. Sexuality 11%
40. Wounds and Injuries 11%
41. potassium titanylphosphate 11%
42. Nocturia 10%
43. Residual Volume 10%
44. Smooth Muscle 10%
45. Multivariate Analysis 9%
46. Actin Depolymerizing Factors 9%
47. Margins of Excision 9%
48. Underactive Urinary Bladder 9%
49. Urge Urinary Incontinence 9%
50. Ureter 9%
51. rho-Associated Kinases 8%
52. Prostatitis 8%
53. Neoplasms 8%
54. Laser Therapy 8%
55. Lithotripsy 8%
56. Urinary Retention 7%
57. Carcinoma 7%
58. Phosphorylation 7%
59. Urine 7%
60. Confidence Intervals 7%
61. Apoptosis 7%
62. Phosphodiesterase 5 Inhibitors 7%
63. Odds Ratio 7%
64. Transurethral Resection of Prostate 7%
65. Meta-Analysis 7%
66. Nomograms 7%
67. Lymph Node Excision 6%
68. Serum 6%
69. Hyperplasia 6%
70. naftopidil 6%
71. Population 6%
72. Regression Analysis 6%
73. Solifenacin Succinate 6%
74. Pressure 6%
75. Vasovasostomy 6%
76. Ejaculation 5%
77. Morcellation 5%
78. mirodenafil 5%
79. Glomerular Filtration Rate 5%
80. Logistic Models 5%
81. Urologists 5%
82. Metabolic Syndrome 5%
83. Phosphotransferases 5%
84. Urinary Bladder Neoplasms 5%
85. Propensity Score 5%
86. Neoplasm Metastasis 5%
87. Area Under Curve 5%
88. Urinary Tract 5%
89. Placebos 5%
90. Linguistics 5%
91. Ureteroscopy 5%
92. Cystectomy 5%
93. Ambulatory Monitoring 5%
94. Sildenafil Citrate 5%
95. Lymph Nodes 5%